^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Prostate Cancer
    Drug:docetaxel (Tubulin polymerization promoter, Microtubule stabilizer)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    07/05/2023
    Excerpt:
    Docetaxel Injection is a microtubule inhibitor indicated for: Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer...
    Secondary therapy:
    prednisone
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Excerpt:
    Docetaxel [ESMO-MCBS v1.1 score: 4] is recommended for men with mCRPC [I, A].
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Prostate Cancer: SYSTEMIC THERAPY FOR M1 CRPC: ADENOCARCINOMA...No prior docetaxel/no prior novel hormone therapy...Prior novel hormone therapy/No prior docetaxel...Preferred regimens...Docetaxel…